A cleantech patent does not have a single fair value. It has a fair value conditional on how the IP is monetised — through licensing, through embedded product sales, or through retention-sensitive customer relationships that the IP underpins. Each monetisation pathway maps to a different valuation method, and choosing the wrong method produces fair values that are off by multiples, not percentages.
Three methods dominate cleantech patent valuation in practice.
Relief-from-Royalty (RFR) values the patent as if the holder were licensing it to a third party. It is the right method where there is an active licensing market for the cluster or where the patent could plausibly be monetised through licensing even where it is not currently being licensed. RFR is the workhorse for cleantech IP — solar, wind, storage and hydrogen all have disclosed comparables.
Multi-Period Excess Earnings (MPEEM) values the patent as the source of excess returns generated by a vertically integrated product. It is the right method where the IP is embedded in a product the company sells and where the excess earnings cannot reasonably be attributed to other identifiable assets. MPEEM is the right answer for cleantech businesses whose IP is core to a sold product, not licensed out.
With-and-Without (W&W) values the patent by modelling cash flows with and without the IP in place. It is the right method where the IP underpins a retention-sensitive relationship — installer networks, certified supply chains, regulatory-approved technology paths — and where loss of the IP would produce a material cash flow loss that is not capturable through a simple royalty rate. See our RFR vs MPEEM vs With-and-Without comparison.
Method selection is the single largest driver of cleantech patent valuation outcome. The same patent valued through RFR, MPEEM and W&W can produce three valuations that differ by multiples. The method must match the monetisation pathway — not the analyst's preference.
The decision tree is straightforward in principle.
| Monetisation pathway | Method | Inputs | Output anchor |
|---|---|---|---|
| Licensable — active market | RFR | Comparable royalty rate, attributable revenue, useful life, discount rate | Avoided licence cost |
| Licensable — plausible market | RFR | Comparable royalty rate (adjacent market), attributable revenue, useful life, discount rate | Hypothetical licence cost |
| Embedded — core product | MPEEM | Excess earnings over contributory asset charges, useful life, discount rate | Capitalised excess earnings |
| Embedded — secondary product | RFR (preferred) or MPEEM | Either set | Either anchor |
| Retention-sensitive relationship | W&W | Cash flow with IP / cash flow without IP, useful life, discount rate | Cash flow differential |
| Defensive / freedom-to-operate | Cost approach (floor) | Replacement / reproduction cost | Cost floor |
| Pre-commercial / standards-essential | RFR with FRAND adjustment | Comparable FRAND rates, projected revenue | Standards-essential anchor |
In practice the trickiest area is the boundary between RFR and MPEEM for embedded technology. The test is whether the excess earnings attributable to the patent can be separated from the excess earnings attributable to other identifiable assets (brand, customer relationships, complementary technology). Where they can be separated cleanly, MPEEM is the right method. Where they cannot, RFR with a defensible comparable rate is more reliable than a MPEEM whose excess-earnings attribution is contestable.
A perovskite specialist holds 8 issued patents across composition and stability chemistry. The IP is currently being licensed to a tier-1 manufacturer at 5.2% of attributable cell revenue. The method is RFR with the directly observed rate. Attributable revenue is the licensee's cell revenue from products incorporating the perovskite layer. Useful life is the shorter of patent expiry and economic obsolescence — typically 10-12 years. Discount rate reflects perovskite-specific technology risk — typically 14-18% for early-commercial perovskite IP. See IP value in solar technology 2026 for the wider solar IP framing.
A wind specialist holds 14 issued patents across blade-tip geometry, vortex generators and pitch-control firmware. The IP is embedded in the company's turbine product — not licensed out — and the excess earnings attributable to the IP can be reasonably separated from the company's brand and customer relationships. The method is MPEEM with contributory asset charges deducted for the manufacturing process, the brand and the customer base. Useful life is 10-15 years. Discount rate sits at 13-15%.
A battery storage specialist holds 12 issued patents across thermal management, state-of-charge optimisation and dispatch logic. The firmware is licensed under FRAND commitments to an industry interoperability standard. The method is RFR with FRAND-adjusted comparable rates — typically 50-70% of non-SEP equivalents. Attributable revenue is the licensee battery system revenue. Useful life is 8-10 years.
A hydrogen specialist holds 6 issued patents across PEM electrolyser stack design and 20+ applications. The IP is embedded in the company's electrolyser product and the company is the sole commercial deployer of the IP. The method depends on substitutability. Where the patents protect a fundamentally differentiated approach (catalyst loading, membrane chemistry), MPEEM is appropriate. Where they protect an incremental improvement (manifold design, sealing geometry), RFR with industrial-equipment comparable rates is more defensible.
A geothermal specialist holds 4 issued patents across enhanced geothermal system (EGS) well-completion technology. The IP underpins a partnership with a tier-1 drilling contractor — the relationship depends on exclusive access to the technology. The method is With-and-Without modelling the cash flow differential between the company retaining and losing the IP. Useful life is 8-12 years.
A UK hydrogen electrolyser business holds 6 issued patents across membrane chemistry and stack design. Applied as RFR with a 3% comparable rate on £25m of attributable revenue over a 10-year life at 16% discount, the IP values at approximately £4.5m. Re-valued as MPEEM with contributory asset charges of 8% on revenue and excess earnings attributed primarily to the patents, the IP values at approximately £18m. The MPEEM answer is right if the excess earnings can be defended as IP-attributable; the RFR answer is right if they cannot. Method selection is the single largest valuation driver.
Cleantech patent valuation operates across three jurisdictions in most multi-asset portfolios. The accounting frameworks converge but the patent-recognition rules and tax positions differ.
Acquired cleantech patents are recognised at fair value at acquisition date under IFRS 3, with subsequent amortisation over useful life under IAS 38. UK patent-box relief applies a 10% effective corporate tax rate to qualifying patent-derived profit — providing a meaningful valuation tailwind on UK-granted patents that flows through into the income-approach calculation (post-tax cash flow).
UK clearing banks increasingly accept cleantech patents as collateral under IP-backed lending pilots — see IP-backed lending for UK renewables.
Acquired cleantech patents are recognised at fair value under ASC 805, with subsequent amortisation under ASC 350. The treatment is substantively identical to IFRS 3 with terminology differences. US tax treatment of qualifying patent IP has been compressed since the 2017 reforms; the Section 174 capitalisation regime now requires capitalisation of certain R&D expenditure that previously expensed, with cleantech R&D specifically benefiting from the §174A election where applicable.
Treatment is consistent with UK IFRS with EU-endorsed wording differences. EU patent court reform (Unified Patent Court) has produced more consistent enforcement outcomes, materially affecting royalty-rate evidence for cleantech IP. EU state-aid rules constrain certain national patent-box equivalents.
| Jurisdiction | Accounting standard | Patent recognition basis | Tax position on patent IP |
|---|---|---|---|
| UK | IFRS 3 / IAS 38 | Fair value at acquisition | Patent box 10% effective rate |
| US | ASC 805 / ASC 350 | Fair value at acquisition | §174A election for cleantech R&D |
| EU | IFRS 3 / IAS 38 (EU-endorsed) | Fair value at acquisition | National patent-box variants |
Cleantech patent valuation methodology is jurisdiction-agnostic; the tax position and enforcement framework differ. UK patent box materially affects post-tax cash flow inputs to RFR and MPEEM. US §174A election affects the cost-approach floor. EU UPC enforcement affects royalty-rate evidence reliability.
Three mistakes recur in cleantech patent valuation.
Defaulting to RFR for embedded technology. RFR is the workhorse but it is not always correct. Where IP is embedded in a vertically integrated product and the excess earnings are cleanly attributable, MPEEM produces a defensible — and often materially higher — value. Defaulting to RFR because it is easier to source comparables can systematically under-value embedded cleantech IP.
Using MPEEM without clean attribution. Where excess earnings cannot be cleanly attributed between the IP and other identifiable assets (brand, customer relationships, complementary technology), MPEEM produces a value that is mathematically computable but legally contestable. The defensible answer is RFR with a comparable-rate-supported royalty.
Aggregating across clusters. A multi-cluster cleantech portfolio (e.g. a platform holding solar tracker, storage and hydrogen IP) should value each cluster separately with its own method selection. Aggregating produces an averaged result that loses the precision of cluster-specific monetisation pathways.
Defensible RFR valuation depends on defensible comparable evidence. Five sources in order of preference.
Where the subject IP is being licensed, the actual rate is the strongest evidence. Adjust for non-arm's-length factors where applicable.
Royalty databases (ktMINE, RoyaltyStat) and litigation-disclosed rates within the same cluster. Adjust for differences in patent strength, geographic scope and remaining life.
UK, EU and US courts have produced reasoned royalty determinations in cleantech disputes since 2023. These provide defensible benchmark rates.
Practitioner surveys (AUTM, LES) provide industry-average ranges. Weakest evidence — should be cross-checked against direct comparables wherever possible.
The fifteen-factor framework provides a structured method for adjusting comparables to the subject IP. Practitioner standard in US patent valuation.
Three actions for cleantech founders and acquirers.
Identify the monetisation pathway before selecting method. Catalogue each patent family by monetisation pathway — licensable, embedded, retention-sensitive, defensive — and let the method follow the pathway.
Catalogue comparable evidence per family. Disclosed licences, royalty databases, litigation rates, industry surveys — the evidence pack should sit alongside each fair-value line item. Opagio Intangibles produces this register through its Asset Valuator module — book a demo.
Cross-check across methods where boundary cases exist. For embedded technology that could plausibly be valued under either RFR or MPEEM, run both methods and disclose the result. The difference itself is informative.
Relief-from-Royalty is the workhorse method, used in roughly two-thirds of cleantech IP valuations. MPEEM accounts for most of the remainder, primarily for vertically integrated technology businesses. With-and-Without is used selectively for retention-sensitive relationships. The right method depends on monetisation pathway, not on practitioner default.
Standards-essential patents (SEPs) subject to FRAND commitments are valued through RFR with an adjusted royalty rate — typically 50-70% of non-SEP equivalents in the same cluster. The FRAND commitment trades higher rate for broader licensing scope. Battery storage and grid-edge inverter patents are common SEP examples in cleantech.
UK patent box reduces the effective corporate tax rate on qualifying patent-derived profit to 10%. It enters the valuation through the cash flow — specifically, the post-tax cash flow used in income-approach calculations — not through the discount rate. Mixing the two is a common mistake that double-counts the benefit.
Yes, with adjustment. US comparables are widely used as evidence in UK valuations and vice versa, particularly where the patent has equivalents in both jurisdictions. Adjustments cover differences in market size, enforcement environment, tax treatment and contract law. The adjustments should be explicit and documented.
The shorter of legal life (20 years from filing, less time elapsed) and economic life (commercial relevance horizon). For fast-moving cleantech clusters (perovskite, battery firmware) economic life is typically 8-12 years. For slower-moving clusters (mechanical wind, geothermal) economic life can extend closer to legal life. Each cluster requires its own assessment.
Opagio Intangibles values cleantech patents through the Asset Valuator module — monetisation-pathway cataloguing per patent family, method selection guided by pathway, comparable-evidence capture, useful life assessment, discount rate calibration to cleantech-cluster-specific risk. Output is an IFRS-3-aligned IP register with audit-defensible method selection. Book a demo.
The methodology is consistent; the inputs differ. Hardware-led cleantech IP (turbine blades, electrolyser stacks) typically uses RFR with industrial-equipment comparables or MPEEM where excess earnings are cleanly attributable. Software-led cleantech IP (tracker firmware, dispatch optimisation, battery management) typically uses RFR with software-licensing comparables, often FRAND-adjusted where standards-essential. The framework holds across both.
Ivan Gowan is the Founder and CEO of Opagio. He brings 25 years of experience building and scaling technology platforms in financial services. Meet the team.
Estimate the value of your intangible assets using industry-standard methods like Relief from Royalty, MPEEM, and With & Without.
Solar technology IP is no longer a niche of crystalline silicon patents. The value wedge in 2026 sits across perovskite tandems, BIPV glazing, agrivoltaics, smart-tracker control, and storage integration. A practitioner view of where IP carries value and how to size it.
Read more →
A comprehensive guide to valuing patented technology as a technology-based intangible asset under IFRS 3. Covers the RFR method, portfolio valuation approaches, patent strength assessment, and the distinction between core and defensive patents.
Read more →
A practical guide to patent valuation covering Relief-from-Royalty, income approach, and cost methods. Includes licensing rate benchmarks by industry, patent strength assessment, and real-world application guidance for IP owners.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how Opagio Intangibles can help your business.